radius-logo-blue.jpg
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
15 août 2022 09h00 HE | Radius Health Inc.
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius...
radius-logo-blue.jpg
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
07 juil. 2022 18h30 HE | Radius Health Inc.
Urges stockholders to vote “FOR” Radius’ highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card...
radius-logo-blue.jpg
Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
07 juil. 2022 08h00 HE | Radius Health Inc.
Advances asset in the neuro-endocrine orphan disease spaceSCOUT-015 clinical trial currently has 9 activated US sites and patient screening commenced30+ global sites are planned for the seamless Phase...
radius-logo-blue.jpg
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital
23 juin 2022 09h15 HE | Radius Health Inc.
Transaction delivers immediate value and liquidity to Radius shareholdersResult of nine-month strategic review process by the Radius Board to maximize shareholder valuePotential per share value of...
radius-logo-blue.jpg
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
22 juin 2022 16h30 HE | Radius Health Inc.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data...
radius-logo-blue.jpg
Radius Health Expands Non-US Market Footprint for TYMLOS
08 juin 2022 08h00 HE | Radius Health Inc.
Globalization has been a key priority for the Company over the past two yearsThree additional market agreements now signed and executed:- Labatec Pharma SA: Switzerland, Middle East & North Africa...
radius-logo-blue.jpg
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
06 juin 2022 09h00 HE | Radius Health Inc.
FLORENCE, Italy and BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the...
radius-logo-blue.jpg
Radius Files Definitive Proxy and Mails Letter to Stockholders
06 juin 2022 07h30 HE | Radius Health Inc.
Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card...
radius-logo-blue.jpg
Radius Health Update on Abaloparatide Transdermal System
01 juin 2022 16h15 HE | Radius Health Inc.
Company ascertained regulatory clarity for possible forward progression of abalo-TDSAdditional and successful clinical trial would be required to advance towards an NDA filingNew timeline for earliest...
radius-logo-blue.jpg
Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors
20 mai 2022 09h00 HE | Radius Health Inc.
Further Expands Board’s Expertise and Gender Diversity Enhances Corporate Governance BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today...